CovidChloroV1, Main, Corpus, bibRecord, 001619

COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?

Identifieur interne : 001619 ( Main/Corpus ); précédent : 001618; suivant : 001620

COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?

Auteurs : Michael F. Marmor

Source :

American journal of ophthalmology [ 1879-1891 ] ; 2020.

RBID : pubmed:32439074

English descriptors

KwdEn :
- Antirheumatic Agents (administration & dosage), Antirheumatic Agents (toxicity), Antiviral Agents (administration & dosage), Antiviral Agents (toxicity), Betacoronavirus (drug effects), COVID-19 (MeSH), China (epidemiology), Chloroquine (administration & dosage), Chloroquine (toxicity), Clinical Trials as Topic (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Humans (MeSH), Hydroxychloroquine (administration & dosage), Hydroxychloroquine (toxicity), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Retina (drug effects), Retina (pathology), Retinal Diseases (chemically induced), Retinal Diseases (diagnosis), SARS-CoV-2 (MeSH).
MESH :
- chemical , administration & dosage : Antirheumatic Agents, Antiviral Agents, Chloroquine, Hydroxychloroquine.
- chemical , toxicity : Antirheumatic Agents, Antiviral Agents, Chloroquine, Hydroxychloroquine.
- geographic , epidemiology : China.
- chemically induced : Retinal Diseases.
- diagnosis : Retinal Diseases.
- drug effects : Betacoronavirus, Retina.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- pathology : Retina.
- COVID-19, Clinical Trials as Topic, Humans, Pandemics, SARS-CoV-2.

DOI: 10.1016/j.ajo.2020.03.029
PubMed: 32439074
PubMed Central: PMC7205730

Links to Exploration step

pubmed:32439074

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?</title>
<author><name sortKey="Marmor, Michael F" sort="Marmor, Michael F" uniqKey="Marmor M" first="Michael F" last="Marmor">Michael F. Marmor</name>
<affiliation><nlm:affiliation>Department of Ophthalmology and Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California. Electronic address: marmor@stanford.edu.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32439074</idno>
<idno type="pmid">32439074</idno>
<idno type="doi">10.1016/j.ajo.2020.03.029</idno>
<idno type="pmc">PMC7205730</idno>
<idno type="wicri:Area/Main/Corpus">001619</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001619</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?</title>
<author><name sortKey="Marmor, Michael F" sort="Marmor, Michael F" uniqKey="Marmor M" first="Michael F" last="Marmor">Michael F. Marmor</name>
<affiliation><nlm:affiliation>Department of Ophthalmology and Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California. Electronic address: marmor@stanford.edu.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">American journal of ophthalmology</title>
<idno type="eISSN">1879-1891</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antirheumatic Agents (administration & dosage)</term>
<term>Antirheumatic Agents (toxicity)</term>
<term>Antiviral Agents (administration & dosage)</term>
<term>Antiviral Agents (toxicity)</term>
<term>Betacoronavirus (drug effects)</term>
<term>COVID-19 (MeSH)</term>
<term>China (epidemiology)</term>
<term>Chloroquine (administration & dosage)</term>
<term>Chloroquine (toxicity)</term>
<term>Clinical Trials as Topic (MeSH)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (administration & dosage)</term>
<term>Hydroxychloroquine (toxicity)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Retina (drug effects)</term>
<term>Retina (pathology)</term>
<term>Retinal Diseases (chemically induced)</term>
<term>Retinal Diseases (diagnosis)</term>
<term>SARS-CoV-2 (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antirheumatic Agents</term>
<term>Antiviral Agents</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Antirheumatic Agents</term>
<term>Antiviral Agents</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>China</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Retinal Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Retinal Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term>
<term>Retina</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Retina</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>COVID-19</term>
<term>Clinical Trials as Topic</term>
<term>Humans</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32439074</PMID>
<DateCompleted><Year>2020</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1891</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>216</Volume>
<PubDate><Year>2020</Year>
<Month>08</Month>
</PubDate>
</JournalIssue>
<Title>American journal of ophthalmology</Title>
<ISOAbbreviation>Am J Ophthalmol</ISOAbbreviation>
</Journal>
<ArticleTitle>COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?</ArticleTitle>
<Pagination><MedlinePgn>A1-A2</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0002-9394(20)30140-9</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajo.2020.03.029</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marmor</LastName>
<ForeName>Michael F</ForeName>
<Initials>MF</Initials>
<AffiliationInfo><Affiliation>Department of Ophthalmology and Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California. Electronic address: marmor@stanford.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>05</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Am J Ophthalmol</MedlineTA>
<NlmUniqueID>0370500</NlmUniqueID>
<ISSNLinking>0002-9394</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012164" MajorTopicYN="N">Retinal Diseases</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>03</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>03</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>03</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>5</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>8</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>5</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32439074</ArticleId>
<ArticleId IdType="pii">S0002-9394(20)30140-9</ArticleId>
<ArticleId IdType="doi">10.1016/j.ajo.2020.03.029</ArticleId>
<ArticleId IdType="pmc">PMC7205730</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2014 Aug;10(8):1380-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24991834</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Ophthalmol. 2014 Dec;132(12):1453-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25275721</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ophthalmology. 2016 Jun;123(6):1386-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26992838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Ophthalmol. 2015 Oct;160(4):799-805.e1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26189086</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Biotechnol. 2020 Apr;38(4):379-381</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205870</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheum. 1999 Feb;42(2):357-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10025931</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 May;55(5):105938</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171740</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheum. 2002 Jun;46(6):1460-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12115175</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2014 Aug;10(8):1391-402</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24991838</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001619 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001619 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32439074
   |texte=   COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:32439074" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?

COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?

Source :

English descriptors

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki